ORIGINAL ARTICLE Year : 2021  |  Volume : 28  |  Issue : 4  |  Page : 211-215  

Evaluation of the systemic inflammation in patients with pterygium: Monocyte-to- high-density lipoprotein cholesterol ratio and hematologic indexes of inflammation

Selman Belviranli, Refik Oltulu, Ali O Gundogan, Enver Mirza, Mehmet Okka
Department of Ophthalmology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

Date of Submission27-Feb-2021Date of Acceptance13-Feb-2022Date of Web Publication30-Apr-2022

Correspondence Address:
Dr. Selman Belviranli
Department of Ophthalmology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya 42080
Turkey

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/meajo.meajo_75_21

   Abstract 

PURPOSE: The purpose of this study is to evaluate systemic inflammation in patients with pterygium using the monocyte-to-high-density lipoprotein cholesterol ratio (MHR) and hematologic indexes of inflammation.
METHODS: Thirty-one patients with primary pterygium and 31 age-and sex-matched healthy participants were enrolled in this retrospective study. The MHR, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, eosinophil-to-lymphocyte ratio, monocyte-to-eosinophil ratio, mean platelet volume-to-platelet count ratio, platelet distribution width, and red cell distribution width were compared between the two groups.
RESULTS: There was not a statistically significant difference in terms of the MHR between the pterygium group and the control group (P = 0.693). The NLR was higher in the pterygium group than in the control group (P = 0.028). In the other hematologic indexes, there were no statistically significant differences between the two groups (P > 0.05 for all).
CONCLUSION: The MHR is not associated with the presence of pterygium. An increased NLR in patients with pterygium may be an indicator of systemic inflammation.

Keywords: Complete blood count, hematologic indexes, inflammation, monocyte-to-HDL cholesterol ratio, pterygium

How to cite this article:
Belviranli S, Oltulu R, Gundogan AO, Mirza E, Okka M. Evaluation of the systemic inflammation in patients with pterygium: Monocyte-to- high-density lipoprotein cholesterol ratio and hematologic indexes of inflammation. Middle East Afr J Ophthalmol 2021;28:211-5
How to cite this URL:
Belviranli S, Oltulu R, Gundogan AO, Mirza E, Okka M. Evaluation of the systemic inflammation in patients with pterygium: Monocyte-to- high-density lipoprotein cholesterol ratio and hematologic indexes of inflammation. Middle East Afr J Ophthalmol [serial online] 2021 [cited 2022 Apr 30];28:211-5. Available from: http://www.meajo.org/text.asp?2021/28/4/211/344451    Introduction 

Pterygium is a wing-shaped conjunctival fibrovascular tissue that crosses over the limbus and invades the corneal surface. The prevalence of pterygium varies in different geographic regions and is higher in tropical areas around the equator, which are known as the “pterygium belt.”[1] A recent meta-analysis revealed that the prevalence of pterygium worldwide is 12%.[2] Sunlight exposure, male gender and older age are the most common risk factors.[2] The pathophysiological mechanisms that underlie the initiation and progression of the pterygium have not been fully understood. In addition to the well-known trigger effect of ultraviolet radiation, recent literature suggests the potential role of inflammatory mechanisms, immunological mechanisms, oxidative stress, genetic factors, and antiapoptotic mechanisms in the pterygium development.[3],[4] Elevated inflammatory mediators in pterygium specimens are signs of the inflammatory process in the pterygium development.[5],[6],[7] In addition to local inflammation, studies suggest that systemic inflammation may also be involved in this process.[8],[9],[10]

Monocytes are subtypes of leukocytes that have an important role in the inflammatory response, while high-density lipoprotein (HDL) cholesterol has anti-inflammatory effects. The monocyte-to-HDL cholesterol ratio (MHR) is examined as an indicator of inflammation in various systemic and ocular diseases.[11],[12],[13]

The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), eosinophil-to-lymphocyte ratio (ELR), monocyte-to-eosinophil ratio (MER), mean platelet volume-to-platelet count ratio (MPV/PC), platelet distribution width (PDW), and red cell distribution width (RDW) have also been proposed as indicators of systemic inflammation in several studies.[14],[15],[16],[17] These indicators are inexpensive and easily available parameters that are derived from complete blood count analyses. In this study, we aimed to evaluate the systemic inflammation in patients with pterygium using the MHR and hematologic indexes of inflammation, including NLR, MLR, PLR, ELR, MER, MPV/PC, PDW, and RDW.

   Methods 

In this study, the medical file records of patients over 18 years of age who applied to the ophthalmology department of a single university hospital between January 2019 and June 2019 and who were diagnosed with primary pterygium in one or two eyes were analyzed retrospectively. Thirty-one patients (16 males, 15 females; mean age: 48.16 ± 13.61 years, range: 25–74 years) who fulfilled the inclusion criteria and who had laboratory data including complete blood count and HDL cholesterol level simultaneously within the past 6 months were enrolled as the “Pterygium Group.” Thirty-one age-and sex-matched healthy participants (16 males, 15 females; mean age: 48.89 ± 11.08 years, range: 31–69 years) who fulfilled the inclusion criteria and who had laboratory data including complete blood count and HDL cholesterol level simultaneously within the past 6 months were enrolled as the “Control Group.” This study was approved by the local clinical research ethics committee and followed the tenets of the Declaration of Helsinki (Decision No: 2019/2187).

Participants in the control group had no ocular pathologies, and participants in the pterygium group had no ocular pathologies other than primary pterygium. Patients with recurrent pterygium were not included in this study. Patients were excluded if they had any systemic disorders that may affect the laboratory findings; if they had a history of ocular or systemic infections, and ocular or any other surgeries within the past 6 months before the laboratory tests; if they had used any form of corticosteroids (including ocular, dermal, inhaler, or systemic), lipid-lowering drugs, or any other medications that may affect the laboratory findings within the past 6 months before the laboratory tests and if they smoked cigarettes or consumed alcohol.

The inflammatory parameters evaluated in the study are (1) MHR: The ratio of monocyte count (/μL)-to-HDL cholesterol level (mg/dL) (2) NLR: the ratio of neutrophil count (/μL)-to-lymphocyte count (/μL)(3) MLR: the ratio of monocyte count (/μL)-to-lymphocyte count (/μL) (4) PLR: the ratio of platelet count (/μL)-to-lymphocyte count (/μL) (5) ELR: The ratio of eosinophil count (/μL)-to-lymphocyte count (/μL) (6) MER: the ratio of monocyte count (/μL)-to-eosinophil count (/μL) (7) MPV/PC: The ratio of mean platelet volume (fL)-to-mean platelet count (/μL) (8) PDW (%): the PDW (9) RDW (%): the RDW.

Statistical analyses of the data were performed using IBM SPSS statistics software version 20.0 (IBM Corp, Armonk, New York, USA). Normality was checked for each continuous variable using the Kolmogorov–Smirnov test. Continuous variables with normal distribution were expressed as the mean ± standard deviation. Continuous variables with nonnormal distribution were expressed as the median interquartile range. Categorical variables were expressed in terms of frequencies. Independent samples–t-test was performed for comparisons among normally distributed variables, and the Mann–Whitney U-test was conducted for comparisons among nonnormally distributed variables. A P < 0.05 was considered statistically significant.

   Results 

There were no statistically significant differences in terms of age and gender between the pterygium group and the control group (P < 0.05). The total number of cases, gender distribution and mean age in the pterygium and control groups are presented in [Table 1].

Table 1: Total number of cases, gender distribution, and mean age in the pterygium and control groups

Click here to view

There was no statistically significant difference in the MHR between the pterygium group and the control group (P = 0.693). The NLR was higher in the pterygium group than in the control group (P = 0.028). For the other hematologic indexes (MLR, PLR, ELR, MER, MPV/PC, PDW, and RDW), there were no statistically significant differences between the pterygium group and the control group (P = 0.693, (P = 0.163, P = 0.081, P = 0.721, P = 0.767, P = 0.606, P = 0.660, and P = 0.091, respectively). Absolute values of the parameters are presented in [Table 2].

Table 2: Monocyte-to-high-density lipoprotein cholesterol ratio and hematologic indexes of inflammation in the pterygium and control groups

Click here to view

   Discussion 

The main characteristics of pterygium development are inflammation, angiogenesis, and fibrosis.[8],[9] Although the exact etiology of the pterygium is not known, ocular surface inflammation has an important role in the pathogenesis of pterygium, regardless of the initiating factor. Many studies in the literature show the locally elevated levels of proinflammatory mediators. Interleukin (IL)-1, IL-6, IL-8, IL-10, and IL-17 are the major interleukins with increased expression in pterygium tissue; these mediators are known to be closely related to inflammation.[3],[4],[5],[6] Kria et al. showed the expression of tumor necrosis factor-alpha in the epithelium, stromal cells, and vascular endothelial cells of the pterygium specimens.[18] Tekelioglu et al. showed the increased levels of inflammatory cells and mediators, including CD4 and CD8 positive lymphocytes, intercellular adhesion molecule-1 positive cells, vascular cell adhesion molecule-1 positive cells, and human leukocyte antigen-DR (HLA-DR) positive cells.[7]

In addition to local inflammation, recent studies have also evaluated the relationship of pterygium with systemic inflammation. Lee et al. showed increased levels of local and systemic endothelial progenitor cells (EPCs) and cytokines, including substance-P, stem cell factor, and vascular endothelial growth factor, in patients with pterygium.[10] EPCs are cells that have a role in postnatal neovascularization. The authors concluded that elevated levels of EPCs induced by the proinflammatory mediators might be associated with angiogenesis in pterygium pathogenesis.[10] Yoo et al. showed the increased serum immunoglobulin E (IgE) levels in patients with pterygium.[9] There is an increased number of mast cells in pterygium.[19] IgE mediates the degranulation of mast cells, and the release of proinflammatory and angiogenic mediators might contribute to the inflammation and angiogenesis in the pterygium pathogenesis.[9],[20] Zidi et al. showed the elevated levels of IL-6, IL-17A, and nitric oxide in both the tear samples and serum samples of patients with pterygium.[8] Furthermore, the elevated systemic oxidant status of patients with pterygium, as shown in a study by Kilic-Toprak et al., may indicate the systemic relationship of pterygium.[21]

Monocytes are subtypes of leukocytes that differentiate into macrophages at the sites of inflammation and release proinflammatory cytokines. They have an important role in the inflammatory response and monocyte count increases in various inflammatory conditions. On the other hand, HDL cholesterol has anti-inflammatory and antioxidative effects. Therefore, in recent literature, MHR has been employed as an indicator of inflammation in various systemic diseases.[11],[22] An increased MHR has also been observed in ocular diseases, including dry eye, branch retinal vein occlusion, central serous chorioretinopathy, and keratoconus.[12],[13],[23],[24] To the best of our knowledge, this is the first study to evaluate the MHR in patients with pterygium. We did not observe an increase in the MHR.

The NLR is a commonly investigated parameter in the evaluation of systemic inflammatory conditions.[15],[25] Ocular disorders, including age-related macular degeneration, retinal vascular diseases, glaucoma, uveitis, and keratoconus, are also associated with an elevated NLR.[26] We observed an elevated NLR in the patients with pterygium in contrast to the findings of Kurtul et al. and Üçgül-Atılgan et al.[14],[27] An elevated NLR may be an indicator of systemic inflammation in patients with pterygium.

In addition to the NLR, MLR (or lymphocyte-to-monocyte count), PLR, ELR, MER (or eosinophil-to-monocyte count), MPV/PC, PDW, and RDW are also employed as indicators of systemic inflammation.[15],[16],[17],[28],[29],[30] However, few studies evaluate these parameters in ocular diseases. In this study, we did not observe an increase in these parameters in the patients with pterygium. Kurtul et al. did not observe an increase in PLR and PDW but revealed an elevated RDW; they concluded that their findings support the role of inflammation in the pathogenesis of pterygium.[14]

This study has some limitations. The first limitation is the retrospective design of the study. Second, many factors can affect the evaluated parameters. We attempted to overcome this problem by strictly applying the inclusion and exclusion criteria to both the case group and the control group. The third limitation is the relatively small sample size.

   Conclusion 

The MHR is not associated with the presence of pterygium. The increased NLR may be an indicator of systemic inflammation in patients with pterygium. Further studies with larger sample sizes and prospective designs are needed to validate these findings.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 

   References 
1.Young AL, Cao D, Chu WK, Ng TK, Yip YW, Jhanji V, et al. The evolving story of pterygium. Cornea 2018;37 Suppl 1:S55-7.  
    2.Rezvan F, Khabazkhoob M, Hooshmand E, Yekta A, Saatchi M, Hashemi H. Prevalence and risk factors of pterygium: A systematic review and meta-analysis. Surv Ophthalmol 2018;63:719-35.  
    3.Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: Role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res 2004;23:195-228.  
    4.Wanzeler AC, Barbosa IA, Duarte B, Borges D, Barbosa EB, Kamiji D, et al. Mechanisms and biomarker candidates in pterygium development. Arq Bras Oftalmol 2019;82:528-36.  
    5.Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 2002;43:3430-7.  
    6.Jabarin B, Solomon A, Amer R. Interleukin-17 and its correlation with vascular endothelial growth factor expression in ocular surface pathologies: A histologic study. Eur J Ophthalmol 2016;26:283-6.  
    7.Tekelioglu Y, Turk A, Avunduk AM, Yulug E. Flow cytometrical analysis of adhesion molecules, T-lymphocyte subpopulations and inflammatory markers in pterygium. Ophthalmologica 2006;220:372-8.  
    8.Zidi S, Bediar-Boulaneb F, Belguendouz H, Belkhelfa M, Medjeber O, Laouar O, et al. Local pro-inflammatory cytokine and nitric oxide responses are elevated in patients with pterygium. Int J Immunopathol Pharmacol 2017;30:395-405.  
    9.Yoo TK, Kim SW, Seo KY. Association between serum immnunoglobulin E and pterygium: A population-based study from South Korea. Curr Eye Res 2018;43:1090-6.  
    10.Lee JK, Song YS, Ha HS, Park JH, Kim MK, Park AJ, et al. Endothelial progenitor cells in pterygium pathogenesis. Eye (Lond) 2007;21:1186-93.  
    11.Canpolat U, Çetin EH, Cetin S, Aydin S, Akboga MK, Yayla C, et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost 2016;22:476-82.  
    12.Şatırtav G, Mirza E, Oltulu R, Mirza GD, Kerimoğlu H. Assessment of monocyte/HDL ratio in branch retinal vein occlusion. Ocul Immunol Inflamm 2020;28:463-7.  
    13.Katipoğlu Z, Mirza E, Oltulu R, Katipoglu B. May monocyte/HDL cholesterol ratio (MHR) and Neutrophil/Lymphocyte Ratio (NLR) be an indicator of inflammation and oxidative stress in patients with keratoconus? Ocul Immunol Inflamm 2020;28:632-6.  
    14.Kurtul BE, Kabatas EU, Ozates S. The correlation of routine hematological indices with pterygium. Ther Adv Ophthalmol 2019;11:2515841419848922.  
    15.Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically ill and injured patients: Which ratio to choose to predict outcome and nature of bacteremia? Mediators Inflamm 2018;2018:3758068.  
    16.Yang Z, Zhang Z, Lin F, Ren Y, Liu D, Zhong R, et al. Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS 2017;125:863-71.  
    17.Cheng S, Han F, Wang Y, Xu Y, Qu T, Ju Y, et al. The red distribution width and the platelet distribution width as prognostic predictors in gastric cancer. BMC Gastroenterol 2017;17:163.  
    18.Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 1996;98:195-201.  
    19.Dilek FH, Öztürk F, Aktepe F, Ermiş S, Mutlu FM. Mast cells and angiogenesis in primary and recurrent pterygia. Turk Patoloji Derg 2007;23:132-6.  
    20.Liang K, Jiang Z, Zhao B, Shen J, Huang D, Tao L. The expression of vascular endothelial growth factor in mast cells promotes the neovascularisation of human pterygia. Br J Ophthalmol 2012;96:1246-51.  
    21.Kilic-Toprak E, Toprak I, Caliskan S, Ozdemir Y, Demirtas O, Altintas F, et al. Oxidative stress and genotoxicity in pterygium: A systemic investigation. Eye Contact Lens 2019;45:399-404.  
    22.Uslu AU, Sekin Y, Tarhan G, Canakcı N, Gunduz M, Karagulle M. Evaluation of monocyte to high-density lipoprotein cholesterol ratio in the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost 2018;24:828-33.  
    23.Yuksel N, Eyidogan Ozdas D, Pasaoglu OT, Pasaoglu H. Elevated monocyte to HDL ratio as a new inflammatory marker in patients with dry eye. New Front Ophthalmol 2018;4:1-3.  
    24.Sirakaya E, Duru Z, Kuçuk B, Duru N. Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy. Indian J Ophthalmol 2020;68:854-8.  
[PUBMED]  [Full text]  25.Mattared AM, Esheba NE, Elshora OA, Mohamed WS. Mean platelet volume and neutrophil to lymphocyte ratio in prediction of early diabetic nephropathy in type 2 diabetics. Diabetes Metab Syndr 2019;13:1469-73.  
    26.Kurtul BE, Ozer PA. Neutrophil-to-lymphocyte ratio in ocular diseases: A systematic review. Int J Ophthalmol 2019;12:1951-8.  
    27.Üçgül-Atılgan C, Kösekahya P, Tekin K, Şendül SY, Çağlayan M, Göker YŞ, et al. The evaluation of neutrophil-to-lymphocyte ratio as a novel marker in patients with pterygium. Turkiye Klinikleri J Ophthalmol 2020;29:52-6  
    28.Fei Y, Zhang H, Zhang C. The application of lymphocyte*platelet and mean platelet volume/platelet ratio in influenza A infection in children. J Clin Lab Anal 2019;33:e22995.  
    29.Sepas HN, Negahi A, Mousavie SH, Nasiri M. Evaluation of the potential association of platelet levels, mean platelet volume and platelet distribution width with acute appendicitis. Open Access Maced J Med Sci 2019;7:2271-6.  
    30.Özbir S, Değirmentepe RB, Atalay HA, Alkan I, Çakır SS, Ötünçtemur A, et al. The role of inflammatory parameters (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-eosinophil ratio) in patients with Peyronie's disease. Andrology 2020;8:348-52.  
    

 
 

  [Table 1], [Table 2]